Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017604803> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2017604803 endingPage "49" @default.
- W2017604803 startingPage "44" @default.
- W2017604803 abstract "Objective: The purpose of this study was to measure the patient acceptance, as well as the individual and provincial cost savings, of switching from other proton pump inhibitor (PPI) therapies to the less costly rabeprazole. Design and setting: This was an uncontrolled, prospective study conducted at a community pharmacy in conjunction with the physicians at the local medical clinic. Patients: Male and female patients over 18 years of age who were currently taking a PPI (omeprazole, lansoprazole, pantoprazole) regularly and who were under the care of a participating physician were eligible. Patients who were pregnant or breast-feeding were excluded. All patients were switched from their current PPI therapy to rabeprazole 20 mg daily, except for two patients, whose previous dose of omeprazole 20 mg twice daily was changed to rabeprazole 20 mg twice daily. Results: Twenty-six patients were enrolled. All patients were Caucasian; 15/26 (58%) were female, and 11/26 (42%) were male; ages ranged from 43 to 89 years. The PPI therapy being used by patients was omeprazole 20 mg, 77% (20/26); pantoprazole 40 mg, 11.5% (3/26); and lansoprazole 30 mg, 11.5% (3/26). At a six-month follow-up (minimum four months of rabeprazole therapy), seven (26.9%) patients had switched back to their original PPI therapy, while 19 (73.1%) had continued on rabeprazole. Five of the seven (71.4%) patients returned to omeprazole therapy, two (28.6%) returned to lansoprazole, and none (0%) returned to pantoprazole. Annual combined cost savings to individual patients was calculated at $4617.48; cost savings to the provincial government were $5083.56. Conclusion: Based on the literature, on the fact that 73.1% of patients found rabeprazole to be equivalent in efficacy and tolerability to the other more costly PPIs, and on the potential cost savings demonstrated, we believe that rabeprazole should be considered as a first choice for PPI therapy." @default.
- W2017604803 created "2016-06-24" @default.
- W2017604803 creator A5013827015 @default.
- W2017604803 creator A5034188642 @default.
- W2017604803 creator A5047882729 @default.
- W2017604803 creator A5065823224 @default.
- W2017604803 creator A5078465724 @default.
- W2017604803 date "2005-06-01" @default.
- W2017604803 modified "2023-09-25" @default.
- W2017604803 title "Patient Acceptance and Economic Outcomes of Rabeprazole Therapy — A Pharmacist-Initiated Interchange Protocol" @default.
- W2017604803 cites W1515870892 @default.
- W2017604803 cites W2033031959 @default.
- W2017604803 cites W2055988464 @default.
- W2017604803 cites W2088820252 @default.
- W2017604803 cites W2129645894 @default.
- W2017604803 cites W213065892 @default.
- W2017604803 doi "https://doi.org/10.1177/171516350513800505" @default.
- W2017604803 hasPublicationYear "2005" @default.
- W2017604803 type Work @default.
- W2017604803 sameAs 2017604803 @default.
- W2017604803 citedByCount "0" @default.
- W2017604803 crossrefType "journal-article" @default.
- W2017604803 hasAuthorship W2017604803A5013827015 @default.
- W2017604803 hasAuthorship W2017604803A5034188642 @default.
- W2017604803 hasAuthorship W2017604803A5047882729 @default.
- W2017604803 hasAuthorship W2017604803A5065823224 @default.
- W2017604803 hasAuthorship W2017604803A5078465724 @default.
- W2017604803 hasConcept C104863432 @default.
- W2017604803 hasConcept C126322002 @default.
- W2017604803 hasConcept C2777498785 @default.
- W2017604803 hasConcept C2778715759 @default.
- W2017604803 hasConcept C2779116819 @default.
- W2017604803 hasConcept C2779457091 @default.
- W2017604803 hasConcept C2781025758 @default.
- W2017604803 hasConcept C2781315423 @default.
- W2017604803 hasConcept C512399662 @default.
- W2017604803 hasConcept C71924100 @default.
- W2017604803 hasConceptScore W2017604803C104863432 @default.
- W2017604803 hasConceptScore W2017604803C126322002 @default.
- W2017604803 hasConceptScore W2017604803C2777498785 @default.
- W2017604803 hasConceptScore W2017604803C2778715759 @default.
- W2017604803 hasConceptScore W2017604803C2779116819 @default.
- W2017604803 hasConceptScore W2017604803C2779457091 @default.
- W2017604803 hasConceptScore W2017604803C2781025758 @default.
- W2017604803 hasConceptScore W2017604803C2781315423 @default.
- W2017604803 hasConceptScore W2017604803C512399662 @default.
- W2017604803 hasConceptScore W2017604803C71924100 @default.
- W2017604803 hasIssue "5" @default.
- W2017604803 hasLocation W20176048031 @default.
- W2017604803 hasOpenAccess W2017604803 @default.
- W2017604803 hasPrimaryLocation W20176048031 @default.
- W2017604803 hasRelatedWork W1950312414 @default.
- W2017604803 hasRelatedWork W1978036783 @default.
- W2017604803 hasRelatedWork W1991944200 @default.
- W2017604803 hasRelatedWork W2016617055 @default.
- W2017604803 hasRelatedWork W2093265279 @default.
- W2017604803 hasRelatedWork W2108533034 @default.
- W2017604803 hasRelatedWork W213065892 @default.
- W2017604803 hasRelatedWork W2369047599 @default.
- W2017604803 hasRelatedWork W4249655679 @default.
- W2017604803 hasRelatedWork W3144860493 @default.
- W2017604803 hasVolume "138" @default.
- W2017604803 isParatext "false" @default.
- W2017604803 isRetracted "false" @default.
- W2017604803 magId "2017604803" @default.
- W2017604803 workType "article" @default.